Compare Novavax Inc (NVAX) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Banco Santander SA — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while Banco Santander SA trades at $13.49 (market cap $192.86B). The key difference: Banco Santander SA is far larger — about 106× Novavax Inc's market cap, and Banco Santander SA pays a 2.06% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Banco Santander SA for 55 Days on average.
| NVAX | SAN | |
|---|---|---|
Market Cap | $1.82B | $192.86B |
Volume | 6,198,505 | 10,644,519 |
Sector | Health | Financials |
52-Week High | $12.56 | $15.05 |
52-Week Low | $6.22 | $9.65 |
Typical Hold Time | 59 Days | 55 Days |
Enterprise Value | $1.39B | $360.86B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
Banco Santander (SAN) trades at $13.48, down 1.32% with bearish technical signals despite strong fundamentals. The stock shows mixed earnings performance with Q1 2026 beat but Q2 miss, while maintaining robust profitability with 26.25% net margin and 16.07% ROE. Recent developments include the completed Webster Financial acquisition expanding U.S. presence and record quarterly profits reported in Q2 2026.
SAN presents a value opportunity with reasonable P/E of 13.55 and strong analyst support (64% buy ratings), though negative cash flow trends and declining operating cash flow from $56.7B in 2021 to -$24.2B in 2024 raise concerns. The Webster integration execution and European banking sector volatility represent key near-term risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
